Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308319542> ?p ?o ?g. }
- W4308319542 endingPage "279" @default.
- W4308319542 startingPage "275" @default.
- W4308319542 abstract "Patients with Alzheimer's disease who have been given monoclonal antibodies targeting amyloid-β (Aβ) (eg, gantenerumab, donanemab, lecanemab, and aducanumab) for scientific purposes may have a spectrum of imaging findings known as amyloid-related imaging abnormalities (ARIA), shown on brain magnetic resonance imaging (MRI) scans. These neuroimaging abnormalities are caused by antibody-mediated destruction of accumulated Aβ aggregates in cerebral blood vessels and brain parenchyma. ARIA may demonstrate as brain edema or sulcal effusion (ARIA-E) or as hemosiderin deposits caused by brain parenchymal or pial hemorrhage (ARIA-H). The current study explores 2 cases with interval development of FLAIR hyper signal intensity along the bilateral corticospinal tracts in the motor cortex/precentral gyri after treatment by aducanumab. We believe this manifestation is a subtype of ARIA-A that has not been explored earlier. Our first case was a 72-year-old woman with a history of HTN and kidney transplant (polycystic kidney) who presented with mild cognitive impairment with clinical findings consistent with early Alzheimer's disease. After receiving 3 doses of aducunumab and experiencing cognition improvement, she underwent a brain MRI because of dizziness and vertigo. The brain MRI demonstrated new FLAIR hyper signal intensity in subcortical regions of precentral gyri (motor cortex) symmetrically as well as trace subarachnoid hemorrhage at the vertex compatible with ARIA-E and ARIA-H. Our second case was an 85-year-old woman with a history of small lymphocytic leukemia which was treated 20 years earlier. After orthopedic surgery 2 years ago, she developed dementia with anterograde amnesia. Since then, Aricept and Namenda have been started, but there have been no improvements in her subjective condition. The initial Amyloid PET/MR imaging showed diffuse cerebral Amyloid deposition. After tolerating 6 doses of aducanumab a safety MRI revealed new bilateral symmetric FLAIR hyper signal intensity in the subcortical motor cortex. Results of our study suggest that the subcortical corticospinal tract is another hotspot for ARIA findings. Hence, these regions might be an unknown site for both the action and adverse effects of aducanumab on amyloid plaques with secondary inflammation. In addition, radiologists must take this phenomenon into the account, and be cognizant that the FLAIR hyper signal intensities should not be misinterpreted as motor neuron disease (eg, amyotrophic lateral sclerosis)." @default.
- W4308319542 created "2022-11-10" @default.
- W4308319542 creator A5002080900 @default.
- W4308319542 creator A5020045704 @default.
- W4308319542 creator A5051108289 @default.
- W4308319542 creator A5078243874 @default.
- W4308319542 creator A5082914362 @default.
- W4308319542 creator A5086782554 @default.
- W4308319542 date "2023-01-01" @default.
- W4308319542 modified "2023-10-14" @default.
- W4308319542 title "Subcortical signal alteration of corticospinal tracts. A radiologic manifestation of ARIA: A case report" @default.
- W4308319542 cites W1509189685 @default.
- W4308319542 cites W1978924496 @default.
- W4308319542 cites W1998616945 @default.
- W4308319542 cites W2010541165 @default.
- W4308319542 cites W2015484447 @default.
- W4308319542 cites W2042282383 @default.
- W4308319542 cites W2074274706 @default.
- W4308319542 cites W2086572083 @default.
- W4308319542 cites W2096947785 @default.
- W4308319542 cites W2108216694 @default.
- W4308319542 cites W2122843800 @default.
- W4308319542 cites W2166411759 @default.
- W4308319542 cites W2265799967 @default.
- W4308319542 cites W2291453643 @default.
- W4308319542 cites W2385703614 @default.
- W4308319542 cites W2423611370 @default.
- W4308319542 cites W2466890096 @default.
- W4308319542 cites W2510806376 @default.
- W4308319542 cites W2593927122 @default.
- W4308319542 cites W2772872651 @default.
- W4308319542 cites W2773427194 @default.
- W4308319542 cites W2777928756 @default.
- W4308319542 cites W2786608785 @default.
- W4308319542 cites W2800202520 @default.
- W4308319542 cites W2883628966 @default.
- W4308319542 cites W2914647279 @default.
- W4308319542 cites W2961385929 @default.
- W4308319542 cites W2969562288 @default.
- W4308319542 cites W2976163884 @default.
- W4308319542 cites W2994050324 @default.
- W4308319542 cites W2995183059 @default.
- W4308319542 cites W3003291611 @default.
- W4308319542 cites W3007853567 @default.
- W4308319542 cites W3048331423 @default.
- W4308319542 cites W3191999594 @default.
- W4308319542 cites W3209578655 @default.
- W4308319542 cites W3217122335 @default.
- W4308319542 cites W4211102779 @default.
- W4308319542 cites W4220825176 @default.
- W4308319542 doi "https://doi.org/10.1016/j.radcr.2022.10.023" @default.
- W4308319542 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36388611" @default.
- W4308319542 hasPublicationYear "2023" @default.
- W4308319542 type Work @default.
- W4308319542 citedByCount "3" @default.
- W4308319542 countsByYear W43083195422023 @default.
- W4308319542 crossrefType "journal-article" @default.
- W4308319542 hasAuthorship W4308319542A5002080900 @default.
- W4308319542 hasAuthorship W4308319542A5020045704 @default.
- W4308319542 hasAuthorship W4308319542A5051108289 @default.
- W4308319542 hasAuthorship W4308319542A5078243874 @default.
- W4308319542 hasAuthorship W4308319542A5082914362 @default.
- W4308319542 hasAuthorship W4308319542A5086782554 @default.
- W4308319542 hasBestOaLocation W43083195421 @default.
- W4308319542 hasConcept C101070640 @default.
- W4308319542 hasConcept C126838900 @default.
- W4308319542 hasConcept C142724271 @default.
- W4308319542 hasConcept C143409427 @default.
- W4308319542 hasConcept C146638467 @default.
- W4308319542 hasConcept C2777790613 @default.
- W4308319542 hasConcept C2779134260 @default.
- W4308319542 hasConcept C2779483572 @default.
- W4308319542 hasConcept C71924100 @default.
- W4308319542 hasConceptScore W4308319542C101070640 @default.
- W4308319542 hasConceptScore W4308319542C126838900 @default.
- W4308319542 hasConceptScore W4308319542C142724271 @default.
- W4308319542 hasConceptScore W4308319542C143409427 @default.
- W4308319542 hasConceptScore W4308319542C146638467 @default.
- W4308319542 hasConceptScore W4308319542C2777790613 @default.
- W4308319542 hasConceptScore W4308319542C2779134260 @default.
- W4308319542 hasConceptScore W4308319542C2779483572 @default.
- W4308319542 hasConceptScore W4308319542C71924100 @default.
- W4308319542 hasIssue "1" @default.
- W4308319542 hasLocation W43083195421 @default.
- W4308319542 hasLocation W43083195422 @default.
- W4308319542 hasLocation W43083195423 @default.
- W4308319542 hasOpenAccess W4308319542 @default.
- W4308319542 hasPrimaryLocation W43083195421 @default.
- W4308319542 hasRelatedWork W2343453685 @default.
- W4308319542 hasRelatedWork W2966120825 @default.
- W4308319542 hasRelatedWork W3013800676 @default.
- W4308319542 hasRelatedWork W3081923296 @default.
- W4308319542 hasRelatedWork W3137967679 @default.
- W4308319542 hasRelatedWork W4225474387 @default.
- W4308319542 hasRelatedWork W4310330293 @default.
- W4308319542 hasRelatedWork W4318262520 @default.
- W4308319542 hasRelatedWork W4319006090 @default.
- W4308319542 hasRelatedWork W4360955463 @default.